Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

NCT05260671 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Neoplasms
Recurrent Disease
Metastatic Cancer

Interventions

DRUG: Penpulimab combined with cetuximab

Sponsor

Eye & ENT Hospital of Fudan University